共 50 条
- [41] The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trialNATURE COMMUNICATIONS, 2025, 16 (01)Mora, JaumeChan, Godfrey C. F.Morgenstern, Daniel A.Amoroso, LoredanaNysom, KarstenFaber, JoergWingerter, ArthurBear, Melissa K.Rubio-San-Simon, Albade las Heras, Blanca MartinezTornoe, KarenDuering, MariaKushner, Brian H.
- [42] Naxitamab and granulocyte macrophage colony stimulating factor (GM- CSF) in combination with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse: An international, single-arm, multicenter phase 2 trial.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Chan, Godfrey Chi-FungHindsberger, CharlotteMorsing, AnniLisby, Steen
- [43] Temozolomide (TMZ) and Irinotecan (IRN) as a Maintenance Therapy for MYCN Non-Amplified High-Risk NeuroblastomaPEDIATRIC BLOOD & CANCER, 2019, 66 : S107 - S108Isshiki, KyoheiKiyotani, ChikakoMatsukawa, YukihiroSugawa, MasahiroMizuno, TakanoriTsujimoto, ShinnichiSakamoto, KennichiUchiyama, MeriOsumi, TomooShioda, YokoKato, MotohiroTerashima, KeitaTomizawa, DaisukeHishiki, TomoroYoshioka, TakakoFuji, HiroshiMiyazaki, OsamuKitamura, MasayukiMatsumoto, Kimikazu
- [44] Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201ANNALS OF ONCOLOGY, 2021, 32 : S833 - S833Mora, J.Bear, M.Chan, G.Morgenstern, D. A.Nysom, K.Tornoe, K.Losic, N.Kushner, B.
- [45] Allogeneic transplantation for patients with high-risk or refractory neuroblastoma.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Driscoll, T. A.Martin, P. L.Moffet, J.Daniel, M.Page, K.Parikh, S.Prasad, V.Szabolcs, P.Kurtzberg, J.
- [46] Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating FactorJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 508 - +Lerman, Benjamin J.Li, YimeiCarlowicz, CeciliaGranger, MeaghanCash, ThomasSadanand, ArhantiSomers, KatherineRanavaya, AeeshaWeiss, Brian D.Choe, MichelleFoster, Jennifer H.Pinto, NavinMorgenstern, Daniel A.Rafael, Margarida SimaoStreby, Keri A.Zeno, Rachel N.Mody, RajenYazdani, SahrDesai, Ami, VMacy, Margaret E.Shusterman, SuzanneFederico, Sara M.Bagatell, Rochelle
- [47] Prognosis of Patients with Relapsed, High-risk Neuroblastoma: A Single Center ExperiencePEDIATRIC BLOOD & CANCER, 2017, 64 : S41 - S42Yamada, YujiKiyotani, ChikakoShioda, YokoOsumi, TomooKato, MotohiroTomizawa, DaisukeTerashima, KeitaHishiki, TomoroFujino, AkihiroKanamori, YutakaFuji, HiroshiYoshioka, TakakoMiyazaki, OsamuMatsumoto, Kimikazu
- [48] Targeted Treatment and Immunotherapy in High-risk and Relapsed/Refractory Pediatric Acute Lymphoblastic LeukemiaCURRENT PEDIATRIC REVIEWS, 2023, 19 (02) : 150 - 156Graiqevci-Uka, VioletaBehluli, EmirSpahiu, LidvanaLiehr, ThomasTemaj, Gazmend
- [49] Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) TrialJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (12) : 1368 - +DuBois, Steven G.Marachelian, ArazFox, ElizabethKudgus, Rachel A.Reid, Joel M.Groshen, SusanMalvar, JemilyBagatell, RochelleWagner, LarsMaris, John M.Hawkins, RandallCourtier, JesseLai, HollieGoodarzian, FaribaShimada, HiroyukiCzarnecki, ScarlettTsao-Wei, DeniceMatthay, Katherine K.Mosse, Yael P.
- [50] Patterns of relapse after immunotherapy in patients with high-risk neuroblastoma.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Moerdler, ScottNaranjo, ArleneTenney, SheenaBagatell, RochelleYu, Alice L.London, Wendy B.